Inter Partes Review
`United States Patent No. 9,815,827
`
`U.S. PATENT NO. 9,815,827 CLAIM LISTING
`Limitation
`
`1. A method
`
`
`
`No.
`1P
`
`1.1
`
`for treating schizophrenia in a patient
`
`1.2 without a clinically significant weight gain, comprising:
`
`1.3
`
`1.4
`
`1.5
`
`1.6
`
`2P
`
`administering orally to the patient
`
`(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically
`acceptable salt thereof
`
`at a dose of from 20 to 120 mg/day such that
`
`the patient does not experience a clinically significant weight gain.
`
`2. The method of claim 1,
`
`2.1 wherein (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-
`yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride is administered.
`
`3P
`
`3.1
`
`3. The method of claim 2, wherein the administering is conducted
`such that
`
`the patient does not experience a clinically significant weight gain
`after six weeks of administration.
`
`4P
`
`4. The method of claim 3,
`
`4.1 wherein the administering is conducted without concurrently
`administering another antipsychotic medication.
`
`5P
`
`5.1
`
`6P
`
`
`{80237647:1}
`
`5. The method of claim 2, further comprising:
`
`detecting a weight gain after six weeks of administration.
`
`6. The method of claim 1,
`
`
`
`
`Page 1 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`United States Patent No. 9,815,827
`
`U.S. PATENT NO. 9,815,827 CLAIM LISTING
`Limitation
`
`1. A method
`
`
`
`No.
`1P
`
`1.1
`
`for treating schizophrenia in a patient
`
`1.2 without a clinically significant weight gain, comprising:
`
`1.3
`
`1.4
`
`1.5
`
`1.6
`
`2P
`
`administering orally to the patient
`
`(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically
`acceptable salt thereof
`
`at a dose of from 20 to 120 mg/day such that
`
`the patient does not experience a clinically significant weight gain.
`
`2. The method of claim 1,
`
`2.1 wherein (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-
`yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride is administered.
`
`3P
`
`3.1
`
`3. The method of claim 2, wherein the administering is conducted
`such that
`
`the patient does not experience a clinically significant weight gain
`after six weeks of administration.
`
`4P
`
`4. The method of claim 3,
`
`4.1 wherein the administering is conducted without concurrently
`administering another antipsychotic medication.
`
`5P
`
`5.1
`
`6P
`
`
`{80237647:1}
`
`5. The method of claim 2, further comprising:
`
`detecting a weight gain after six weeks of administration.
`
`6. The method of claim 1,
`
`
`
`
`Page 1 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`
`Limitation
`No.
`6.1 wherein said patient has a BPRS score of at least 42 and wherein
`
`6.2
`
`the patient's BPRS score is significantly reduced from a baseline
`measurement prior to the administering.
`
`7P
`
`7. The method of claim 3,
`
`7.1 wherein the dose is from 40 to 120 mg once daily.
`
`8P
`
`8.1
`
`8. A method
`
`for treating manic depressive psychosis in a patient
`
`8.2 without a clinically significant weight gain, comprising:
`
`8.3
`
`8.4
`
`8.5
`
`8.6
`
`9P
`
`administering orally to the patient
`
`(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically
`acceptable salt thereof
`
`at a dose of from 20 to 120 mg/day such that
`
`the patient does not experience a clinically significant weight gain.
`
`9. The method of claim 8,
`
`9.1 wherein (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-
`yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride is administered.
`
`10P 10. The method of claim 9,
`
`10.1 wherein the administering is conducted such that the patient does
`not experience a clinically significant weight gain after six weeks
`of administration.
`
`11P 11. The method of claim 9, further comprising:
`
`11.1 detecting a weight gain after six weeks of administration.
`
`
`{80237647:1}
`
`
`Page 2 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`
`Limitation
`No.
`12P 12. The method of claim 10,
`
`12.1 wherein the administering is conducted without concurrently
`administering another antipsychotic medication.
`
`13P 13. The method of claim 10,
`
`13.1 wherein the dose is 20 mg once daily.
`
`14P 14. The method of claim 10,
`
`14.1 wherein the dose is 40 mg once daily.
`
`15P 15. The method of claim 10,
`
`15.1 wherein the dose is 60 mg once daily.
`
`16P 16. The method of claim 10,
`
`16.1 wherein the dose is 80 mg once daily.
`
`17P 17. The method of claim 10,
`
`17.1 wherein the dose is 120 mg once daily.
`
`18P 18. The method of claim 9,
`
`18.1 wherein the dose is 20 mg, 40 mg, 60 mg, 80 mg or 120 mg once
`daily.
`
`19P 19. The method of claim 3,
`
`19.1 wherein the dose is 20 mg once daily.
`
`20P 20. The method of claim 3,
`
`20.1 wherein the dose is 40 mg once daily.
`
`21P 21. The method of claim 3,
`
`21.1 wherein the dose is 60 mg once daily.
`
`
`{80237647:1}
`
`
`Page 3 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`
`Limitation
`No.
`22P 22. The method of claim 3,
`
`22.1 wherein the dose is 80 mg once daily.
`
`23P 23. The method of claim 3,
`
`23.1 wherein the dose is 120 mg once daily.
`
`24P 24. The method of claim 2,
`
`24.1 wherein the dose is 20 mg, 40 mg, 60 mg, 80 mg or 120 mg once
`daily.
`
`25P 25. A method
`
`25.1 of treating a patient with an antipsychotic
`
`25.2 without a clinically significant weight gain in the patient,
`comprising:
`
`25.3 orally administering the antipsychotic to the patient
`
`25.4 once daily at a dose of from 20 to 120 mg such that
`
`25.5 the patient does not experience a clinically significant weight gain,
`
`25.6 wherein the antipsychotic is (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-
`benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-
`2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically
`acceptable salt thereof.
`
`26P 26. The method of claim 25,
`
`26.1 wherein the antipsychotic is (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-
`benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-
`2,3-bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`27P 27. The method of claim 26,
`
`
`{80237647:1}
`
`
`Page 4 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`
`Limitation
`No.
`27.1 wherein the administering is conducted such that the patient does
`not experience a clinically significant weight gain after six weeks
`of administration.
`
`28P 28. The method of claim 26, further comprising:
`
`28.1 detecting a weight gain after six weeks of administration.
`
`29P 29. The method of claim 27,
`
`29.1 wherein the method treats schizophrenia in the patient.
`
`30P 30. The method of claim 27,
`
`30.1 wherein the method treats manic depressive psychosis in the
`patient.
`
`31P 31. The method of claim 25,
`
`31.1 wherein the method treats the patient without the patient
`experiencing a weight gain.
`
`32P 32. The method of claim 29,
`
`32.1 wherein the administering is conducted without concurrently
`administering another antipsychotic medication.
`
`33P 33. The method of claim 30,
`
`33.1 wherein the administering is conducted without concurrently
`administering another antipsychotic medication.
`
`34P 34. The method of claim 27,
`
`34.1 wherein the dose is 20 mg.
`
`35P 35. The method of claim 27,
`
`35.1 wherein the dose is 40 mg.
`
`36P 36. The method of claim 27,
`
`
`{80237647:1}
`
`
`Page 5 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`
`No.
`36.1 wherein the dose is 60 mg.
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`Limitation
`
`37P 37. The method of claim 27,
`
`37.1 wherein the dose is 80 mg.
`
`38P 38. The method of claim 27,
`
`38.1 wherein the dose is 120 mg.
`
`39P 39. The method of claim 26,
`
`39.1 wherein the dose is 20 mg, 40 mg, 60 mg, 80 mg or 120 mg.
`
`40P 40. A method
`
`40.1 of treating a patient with an antipsychotic
`
`40.2 without a clinically significant weight gain, comprising:
`
`40.3 orally administering
`
`40.4 once daily to the patient
`
`40.5 a pharmaceutical composition comprising 20 to 120 mg of
`
`40.6 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically
`acceptable salt thereof
`
`40.7 as a sole active ingredient such that
`
`40.8 the patient does not experience a clinically significant weight gain.
`
`41P 41. The method of claim 40,
`
`41.1 wherein the sole active ingredient is (1R,2S,3R,4S)-N-[(1R,2R)-2-
`[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-
`cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide
`hydrochloride.
`
`
`{80237647:1}
`
`
`Page 6 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`
`Limitation
`No.
`42P 42. The method of claim 41,
`
`42.1 wherein the pharmaceutical composition is a tablet.
`
`43P 43. The method of claim 41,
`
`43.1 wherein the administering is conducted such that the patient does
`not experience a clinically significant weight gain after six weeks
`of administration.
`
`44P 44. The method of claim 41, further comprising:
`
`44.1 detecting a weight gain after six weeks of administration.
`
`45P 45. The method of claim 43,
`
`45.1 wherein the method treats schizophrenia in the patient.
`
`46P 46. The method of claim 43,
`
`46.1 wherein the method treats manic depressive psychosis in the
`patient.
`
`47P 47. The method of claim 45,
`
`47.1 wherein the administering is conducted without concurrently
`administering another antipsychotic medication.
`
`48P 48. The method of claim 46,
`
`48.1 wherein the administering is conducted without concurrently
`administering another antipsychotic medication.
`
`49P 49. The method of claim 41,
`
`49.1 wherein the pharmaceutical composition includes 40 to 120 mg of
`
`49.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`
`{80237647:1}
`
`
`Page 7 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`
`Limitation
`No.
`50P 50. The method of claim 41,
`
`50.1 wherein the pharmaceutical composition includes 20 mg, 40 mg,
`60 mg, 80 mg or 120 mg of
`
`50.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`51P 51. The method of claim 41,
`
`51.1 wherein the pharmaceutical composition includes 20 mg of
`
`51.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`52P 52. The method of claim 41,
`
`52.1 wherein the pharmaceutical composition includes 40 mg of
`
`52.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`53P 53. The method of claim 41,
`
`53.1 wherein the pharmaceutical composition includes 60 mg of
`
`53.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`54P 54. The method of claim 41,
`
`54.1 wherein the pharmaceutical composition includes 80 mg of
`
`54.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`
`{80237647:1}
`
`
`Page 8 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`
`Limitation
`No.
`55P 55. The method of claim 41,
`
`55.1 wherein the pharmaceutical composition includes 120 mg of
`
`55.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`56P 56. A method
`
`56.1 of treating a patient with an antipsychotic
`
`56.2 without a weight gain, comprising:
`
`56.3 orally administering
`
`56.4 once daily to the patient
`
`56.5 a pharmaceutical composition comprising 20 to 120 mg of
`
`56.6 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically
`acceptable salt thereof
`
`56.7 as a sole active ingredient such that
`
`56.8 the patient does not experience a weight gain.
`
`57P 57. The method of claim 56,
`
`57.1 wherein the sole active ingredient is (1R,2S,3R,4S)-N-[(1R,2R)-2-
`[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-
`cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide
`hydrochloride.
`
`58P 58. The method of claim 57,
`
`58.1 wherein the pharmaceutical composition is a tablet.
`
`59P 59. The method of claim 57,
`
`
`{80237647:1}
`
`
`Page 9 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`
`Limitation
`No.
`59.1 wherein the administering is conducted such that the patient does
`not experience a weight gain after six weeks of administration.
`
`60P 60. The method of claim 57, further comprising:
`
`60.1 detecting a weight gain after six weeks of administration.
`
`61P 61. The method of claim 57,
`
`61.1 wherein the method treats schizophrenia in the patient.
`
`62P 62. The method of claim 57,
`
`62.1 wherein the method treats manic depressive psychosis in the
`patient.
`
`63P 63. The method of claim 61,
`
`63.1 wherein the administering is conducted without concurrently
`administering another antipsychotic medication.
`
`64P 64. The method of claim 62,
`
`64.1 wherein the administering is conducted without concurrently
`administering another antipsychotic medication.
`
`65P 65. The method of claim 61,
`
`65.1 wherein the pharmaceutical composition includes 40 to 120 mg of
`(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`66P 66. The method of claim 57,
`
`66.1 wherein the pharmaceutical composition includes 20 mg, 40 mg,
`60 mg, 80 mg or 120 mg of
`
`66.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`
`{80237647:1}
`
`
`Page 10 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`
`Limitation
`No.
`67P 67. The method of claim 62,
`
`67.1 wherein the pharmaceutical composition includes 20 mg of
`
`67.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`68P 68. The method of claim 61,
`
`68.1 wherein the pharmaceutical composition includes 40 mg of
`
`68.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`69P 69. The method of claim 62,
`
`69.1 wherein the pharmaceutical composition includes 40 mg of
`
`69.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`70P 70. The method of claim 61
`
`70.1 wherein the pharmaceutical composition includes 60 mg of
`
`70.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`71P 71. The method of claim 62
`
`71.1 wherein the pharmaceutical composition includes 60 mg of
`
`71.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`72P 72. The method of claim 61,
`
`
`{80237647:1}
`
`
`Page 11 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
`
`Inter Partes Review
`United States Patent No. 9,815,827
`
`
`Limitation
`No.
`72.1 wherein the pharmaceutical composition includes 80 mg of
`
`72.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`73P 73. The method of claim 62,
`
`73.1 wherein the pharmaceutical composition includes 80 mg of
`
`73.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`74P 74. The method of claim 61,
`
`74.1 wherein the pharmaceutical composition includes 120 mg of
`
`74.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`75P 75. The method of claim 62,
`
`75.1 wherein the pharmaceutical composition includes 120 mg of
`
`75.2 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1 -
`piperazinylmethyl]-1-cyclohexylmethyl]-2,3-
`bicyclo[2.2.1]heptanedicarboximide hydrochloride.
`
`
`
`
`{80237647:1}
`
`
`Page 12 of 12
`
`SLAYBACK EXHIBIT 1050
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
